Filing summary
Period and entity: The supplied filing is MEI Pharma, Inc.’s unaudited Form 10-Q for the quarter and six months ended December 31, 2020—not Lite Strategy, Inc.’s 2019 Q2 filing as stated in the request metadata. The summary below reflects the filing text.
Business context and reporting period
MEI Pharma is a clinical-stage oncology company. Its four clinical-stage candidates are zandelisib, voruciclib, ME-344 and pracinostat. Zandelisib is the lead program; the company was conducting a Phase 2 trial intended to support a potential FDA accelerated-approval application. The filing compares the three and six months ended December 31, 2020 with the corresponding 2019 periods.
Financial performance and position
| Metric | Three months ended Dec. 31, 2020 | Six months ended Dec. 31, 2020 | Comparable 2019 period |
|---|---|---|---|
| Revenue | $9.2 million | $13.0 million | $1.0 million and $2.2 million, respectively |
| Operating expenses | $28.4 million | $47.8 million | $13.1 million and $26.9 million |
| Loss from operations | $19.2 million | $34.8 million | $12.1 million and $24.7 million |
| Net loss | $11.5 million | $13.5 million | $20.2 million and $23.2 million |
| Basic net loss per share | $0.10 | $0.12 | $0.26 and $0.30 |
| Net cash used in operating activities | $5.1 million for six months | $24.6 million for six months |
Revenue was principally recognized under the KKC collaboration agreements: $9.1 million for the quarter and $12.7 million for the six-month period. Operating costs rose substantially, led by zandelisib trial activity and trial start-up costs. Net loss was lower than the prior-year periods largely because of noncash gains from remeasuring warrant liabilities: $7.1 million for the quarter and $20.3 million for six months. Basic net loss excludes this warrant-related effect; the filing reports diluted net loss of $18.5 million for the quarter and $33.9 million for six months after the applicable adjustment.
At December 31, 2020, cash, cash equivalents and short-term investments totaled $180.1 million, including $170.3 million in U.S. government securities. Total assets were $203.9 million; total liabilities were $130.4 million; and stockholders’ equity was $73.5 million. The filing identifies no conventional borrowings. Liabilities included $84.8 million of deferred revenue, a $20.2 million warrant liability and $8.7 million of operating lease liabilities. The company reported a six-month net decrease in cash of $2.5 million and ending cash and cash equivalents of $9.9 million. The reduction in operating cash use versus 2019 was materially affected by collection of a $20.4 million Japanese tax-withholding receivable.
Material changes versus the prior comparable periods
- Six-month revenue increased to $13.0 million from $2.2 million, mainly from KKC-related performance obligations.
- Six-month operating expenses increased to $47.8 million from $26.9 million. R&D rose to $35.2 million from $17.2 million, primarily due to zandelisib clinical-trial activity; G&A rose to $11.6 million from $8.3 million.
- Despite higher operating losses, reported net loss narrowed, mainly due to the warrant-liability fair-value gain rather than improved operating performance.
- The company received the $20.4 million Japanese tax-withholding receivable in October 2020. It also issued 958,083 shares through its prior ATM program for net proceeds of $3.1 million during the six months.
Outlook, commentary and risks
- Management expects continued operating losses, negative operating cash flows and increasing R&D spending. It said available resources should fund operations for at least 12 months from issuance and, in MD&A, into fiscal 2022 and beyond. It expects to pursue future financing or partnerships, with no assurance of obtaining capital on acceptable terms.
- Topline data from the Phase 2 TIDAL zandelisib study was expected in the fourth calendar quarter of 2021. Enrollment continued but at a reduced rate amid COVID-19; management warned of possible trial delays, disruptions to sites and supply, and impacts on data integrity and regulatory timelines.
- KKC paid $100 million under the 2020 agreement. MEI may receive up to approximately $582.5 million in development, regulatory and commercialization milestones, plus tiered ex-U.S. royalties. These are contingent potential payments, not assured proceeds. MEI and KKC share U.S. development costs and profits 50-50.
- Helsinn discontinued the Phase 3 pracinostat AML study in July 2020 after an interim futility analysis and withdrew the FDA breakthrough therapy designation for that combination. The pracinostat MDS study had completed treatment and follow-up, with analyses underway for a final report; the filing says no patients remained under treatment or follow-up at December 2020.
- Two related legal matters remained unresolved: a securities class action alleging pracinostat-related misstatements and consolidated stockholder derivative litigation. MEI disputed the claims; outcomes and potential losses were not estimable, and no loss was accrued.
- Other material risks include clinical and regulatory uncertainty, reliance on collaborators and third parties, future financing needs, competition, intellectual-property risks, and milestone or royalty obligations. Potential milestone payments under the Presage and S*Bio agreements had not been accrued because their triggering conditions had not been met.
Most important facts for an investor to verify
- Confirm the filing identity and period: the source is MEI Pharma’s quarter ended December 31, 2020, not the entity and period in the request metadata.
- Check subsequent TIDAL results and any changes to the expected data timing, enrollment, regulatory plans or clinical-development budget.
- Assess cash runway using current cash burn and planned trial spending; distinguish management’s runway estimates from the cash balance and the one-time tax-receivable collection.
- Review KKC collaboration revenue recognition, deferred revenue, cost-sharing assumptions and the terms and conditions attached to contingent milestones and royalties.
- Track the pracinostat program’s disposition and any developments in the securities and derivative litigation.
- Consider potential dilution from outstanding options and 16.1 million warrants, as well as the remaining $60 million ATM capacity and other shelf-registration capacity.